CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Liabilities | ₹32,130 Cr | ₹29,007 Cr | ₹26,652 Cr | ₹24,837 Cr | ₹23,423 Cr |
What is the latest Total Liabilities ratio of CIPLA ?
Year | Total Liabilities |
---|---|
Mar2024 | ₹32,130 Cr |
Mar2023 | ₹29,007 Cr |
Mar2022 | ₹26,652 Cr |
Mar2021 | ₹24,837 Cr |
Mar2020 | ₹23,423 Cr |
How is Total Liabilities of CIPLA Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹32,130 Cr | 10.77 | |
Mar2023 | ₹29,007 Cr | 8.83 | |
Mar2022 | ₹26,652 Cr | 7.31 | |
Mar2021 | ₹24,837 Cr | 6.04 | |
Mar2020 | ₹23,423 Cr | - |
Compare Total Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹120,033.6 Cr | -0.9% | -1.7% | 17.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹431,352.0 Cr | 1.7% | -4.7% | 48.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,265.0 Cr | 4.4% | 3.1% | 66% | Stock Analytics | |
MANKIND PHARMA | ₹102,231.0 Cr | -2.1% | -0.6% | 33.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,286.0 Cr | -1% | -8.9% | 6.5% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,461.4 Cr | -1% | -4% | 48.4% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -0.9% |
-1.7% |
17.3% |
SENSEX | 1.8% |
-2.5% |
19.9% |
You may also like the below Video Courses